



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 160502

TO: Shailendra Kumar
Location: 5c03 / 5c18
Friday, August 05, 2005
Art Unit: 1621
Phone: 571-272-0640
Serial Number: 10 / 828601

From: Jan Delaval
Location: Biotech-Chem Library
Remsen 1a51
Phone: 571-272-2504

jan.delaval@uspto.gov

Search Notes

Jan. please

Access DB# 160502

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: S. Kumar Examiner #: 69594 Date: 7/26/05
 Art Unit: 1621 Phone Number #: 2-0640 Serial Number: 101828601
 Mail Box and Bldg/Room Location: REM 5003 Results Format Preferred (circle): PAPER DISK E-MAIL
5C18


If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: Lidocaine analogs and methods of making and using them
 Inventors (please provide full names): Victor P. Chu et al

Earliest Priority Filing Date: 4/22/04

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



Z is nucleophilic group and optionally a protecting group
 L is linker
 R1 - R5 are H, protecting group, or aryl
 R1 & R3 together may form ring

STAFF USE ONLY

Searcher: [Signature]
 Searcher Phone #: 22504
 Searcher Location: 8/5/05
 Date Searcher Picked Up: 8/5/05
 Date Completed: 8/5/05
 Searcher Prep Review Time: 15
 Clerical Prep Time: 735
 Online Time

Type of Search

NA Sequence (#) _____
 AA Sequence (#) _____
 Structure (#) ✓
 Bibliographic _____
 Litigation _____
 Fulltext _____
 Patent Family _____
 Other _____

Vendors and cost where applicable

STN ✓
 Dialog _____
 Questel/Orbit _____
 Dr. Link _____
 Lexis/Nexis _____
 Sequence Systems _____
 WWW/Internet _____
 Other (specify) _____

=> fil reg

FILE 'REGISTRY' ENTERED AT 09:56:16 ON 05 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 AUG 2005 HIGHEST RN 858414-27-4

DICTIONARY FILE UPDATES: 4 AUG 2005 HIGHEST RN 858414-27-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```


Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sta que 120

L13 STR



VAR G1=4/5/6

NODE ATTRIBUTES:

NSPEC IS RC AT 11

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RSPEC 1

NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

L15 5958 SEA FILE=REGISTRY SSS FUL L13

L18 STR



NODE ATTRIBUTES:

NSPEC IS RC AT 11

CONNECT IS E1 RC AT 12

CONNECT IS E1 RC AT 14

CONNECT IS E1 RC AT 15

CONNECT IS E1 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L20 18 SEA FILE=REGISTRY SUB=L15 SSS FUL L18

```
100.0% PROCESSED      3102 ITERATIONS .
```

18 ANSWERS

SEARCH TIME: 00.00.01

=> d his

(FILE 'HCAPLUS' ENTERED AT 09:28:10 ON 05 AUG 2005)

DEL HIS

E CHU V/AU

L1 173 S E3, E6, E26, E32, E33

E TENG Z/AU

L2 22 S E3-E5 OR TENG ZHU?/AU

E LEWISCH S/AU

L3 5 S E4

E EDWARDS R/AU

L4 306 S E3, E20-E22

E EDWARDS RON/AU

L5 4 S E3, E6, E13

L6 510 S L1-L5

L7 . 0 S L6 AND ?LIDOCAIN?

L8 8 S L6 AND BENZ?/SC,SX

L9 0 S L1 AND L2-L5

L10 0 S L2 AND L3-L5

L11 0 S L3 AND L4,L5

L12 0 S L4 AND L5

FILE 'REGISTRY' ENTERED AT 09:30:46 ON 05 AUG 2005

L13 STR
L14 50 S L13
L15 5958 S L13 FUL
SAV L15 KUMAR828/A
L16 0 S L15 AND C21H37N5O2
L17 0 S L15 AND C24H41N5O5
L18 STR L13
L19 2 S L18 SAM SUB=L15
L20 18 S L18 FUL SUB=L15
SAV L20 KUMAR828A/A
L21 332 S L15 AND PMS/CI
L22 0 S L21 AND (LATEX OR STARCH)
L23 1 S STARCH/CN
L24 0 S 9005-25-8/CRN AND L15
L25 16 S L15 AND OC2/ES

FILE 'HCAPLUS' ENTERED AT 09:47:08 ON 05 AUG 2005

L26 2747 S L15
L27 0 S L6 AND L26
L28 0 S L26 AND (DADE? OR BEHRING? OR DEUTSCHE BANK?)/PA,CS
L29 6 S L26 AND ?LIDOCAINE?

FILE 'REGISTRY' ENTERED AT 09:49:05 ON 05 AUG 2005

L30 1 S LIDOCAINE/CN
L31 248 S 137-58-6/CRN

FILE 'HCAPLUS' ENTERED AT 09:49:28 ON 05 AUG 2005

L32 7 S L30 AND L26
L33 0 S L31 AND L26
L34 9 S L29,L32
L35 42 S L26 AND ?LATEX?
L36 37 S L26 AND ?RUBBER?
L37 7 S L26 AND ?ELASTOM?
E LATEX/CT
E E3+ALL
L38 6573 S E4+NT
E E10+ALL
L39 14600 S E6+OLD,NT
L40 4 S L26 AND L38,L39

FILE 'REGISTRY' ENTERED AT 09:53:32 ON 05 AUG 2005

L41 STR L18
L42 50 S L41 SAM SUB=L15
L43 2298 S L41 FUL SUB=L15


FILE 'HCAPLUS' ENTERED AT 09:55:22 ON 05 AUG 2005

L44 1 S L34 AND L35-L37,L40
L45 9 S L34,L44

FILE 'REGISTRY' ENTERED AT 09:56:16 ON 05 AUG 2005

=> d scan 120


L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-
[[[(phenylmethyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C22 H30 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):17

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Acetamide, N-[3-(acetylamino)-2,6-dimethylphenyl]-2-(diethylamino)- (9CI)
 MF C16 H25 N3 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-
 [[(phenylamino)carbonyl]amino]phenyl]- (9CI)
 MF C21 H28 N4 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Acetamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-[2-(2-methoxyethoxy)ethoxy]- (9CI)
 MF C21 H35 N3 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 2-Propenamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-, homopolymer (9CI)
 MF (C17 H25 N3 O2)x
 CI PMS
 CM 1




L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]phenyl]- (9CI)
 MF C22 H27 F3 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Tetradecanamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-
(9CI)
MF C28 H49 N3 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-3-(trifluoromethyl)- (9CI)
MF C22 H26 F3 N3 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-(2-methoxyethoxy)- (9CI)
MF C19 H31 N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1H-Pyrrol-1-yloxy, 3-[[[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]amino]carbonyl]-2,5-dihydro-2,2,5,5-tetramethyl- (9CI)
 MF C23 H35 N4 O3



L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[[(1S)-1-phenylethyl]amino]carbonyl]amino]phenyl]- (9CI)
 MF C23 H32 N4 O2


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 2,5,8,11-Tetraoxatetradecan-14-amide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl] - (9CI)
 MF C24 H41 N3 O6

PAGE 1-A




PAGE 1-B

—CH₂—NEt₂

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 9-Tetradecenamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl] - (9Z) - (9CI)
 MF C28 H47 N3 O2

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Hexanamide, N-[3-[[diethylamino)acetyl]amino]-2,4-dimethylphenyl]- (9CI)
 MF C20 H33 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Benzamide, 4-chloro-N-[3-[[diethylamino)acetyl]amino]-2,4-dimethylphenyl]-
 (9CI)
 MF C21 H26 Cl N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[(1R)-1-phenylethyl]amino]carbonyl]amino]phenyl]- (9CI)
MF C23 H32 N4 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Acetamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-methoxy- (9CI)
MF C17 H27 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 18 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Propenamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]- (9CI)
MF C17 H25 N3 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d ide can l30

L30 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 137-58-6 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2',6'-Acetoxylicide, 2-(diethylamino)- (8CI)
 OTHER NAMES:
 CN α -Diethylamino-2,6-acetoxylicide
 CN 2-(Diethylamino)-2',6'-acetoxylicide
 CN 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
 CN Anbesol
 CN Anestacon
 CN Cuivasil
 CN Dalcaine
 CN Duncaine
 CN ELA-Max
 CN Esracaine
 CN Isicaina
 CN Isicaine
 CN Jetocaine
 CN Leostesin
 CN Lida-Mantle
 CN Lidocadren
 CN **Lidocaine**
 CN Lidoderm
 CN Lignocaine
 CN LMX
 CN Maricaine
 CN Medicaine
 CN NSC 40030
 CN Penles
 CN Remicaine
 CN Rucaina
 CN Solarcaine
 CN Solcain
 CN Xilina
 CN Xycaine
 CN Xylestesin
 CN Xylene
 CN Xylocain

CN Xylocaine
CN Xylocitin
FS 3D CONCORD
DR 8059-42-5, 8059-66-3, 91484-71-8
MF C14 H22 N2 O
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DIOGENES,
DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA,
MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PIRA, PROMT, PS, RTECS*,
SCISEARCH, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8056 REFERENCES IN FILE CA (1907 TO DATE)
93 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8068 REFERENCES IN FILE CAPLUS (1907 TO DATE)
31 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 143:125378
REFERENCE 2: 143:120573
REFERENCE 3: 143:120552
REFERENCE 4: 143:120541
REFERENCE 5: 143:120528
REFERENCE 6: 143:120253
REFERENCE 7: 143:115675
REFERENCE 8: 143:110722
REFERENCE 9: 143:110715
REFERENCE 10: 143:109819

=> fil hcaplus.
FILE 'HCAPLUS' ENTERED AT 09:56:53 ON 05 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Aug 2005 VOL 143 ISS 7
FILE LAST UPDATED: 4 Aug 2005 (20050804/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 145 all hitstr tot

L45 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:259820 HCAPLUS
DN 142:336135
ED Entered STN: 25 Mar 2005
TI Preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation
IN Baker, William R.; Stasiak, Marcin; Macleod, David
PA Corus Pharma, USA
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 27, 28, 63
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2005025498 | A2 | 20050324 | WO 2004-US28063 | 20040826 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |


PRAI US 2003-501137P P. 20030908

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---------------|--------|------------------------------------|
| WO 2005025498 | ICM | A61K |
| WO 2005025498 | ECLA | A61K009/00M20B |
| OS | MARPAT | 142:336135 |

jan delaval - 5 august 2005

GI



- AB Title compds. [I; X, Y = NH, O, SO₂, CO; n = 1-5; W, Z = H, NH, NR, O, CH₂; R = alkyl, (substituted) alkenyl; when Z = H, then R₁W is absent and when W is absent, R₁ is bonded directly to Z; R₆B is absent and when B is absent, R₆ is bonded directly to A; R₁, R₆ = H, alkylheterocyclyl, (substituted) alkylaryl, biaryl, aralkyl, alkoxy, alkoxyalkyl, alkyl, alkenyl, alkoxyaryl, alkylaryl, alkyl; R₂, R₃ = H, Me; R₄, R₅ = H, alkyl; R₄R₅ = atoms to form a (substituted) 2-10 membered ring], were prepared Thus, N-(3-amino-2,6-dimethylphenyl)-2-[1,4']-bipiperidin-1'-ylacetamide (preparation given) was stirred with 6-(4-phenylbutoxy)hexanal and NaBH(OAc)₃ in CH₂Cl₂ at 0-5° to give 2-[1,4']bipiperidin-1'-yl-N-[2,6-dimethyl-3-[6-(4-phenylbutoxy)hexylamino]phenyl]acetamide. The latter inhibited eosinophil survival with IC₅₀ = 5 μM.
- ST acetanilide benzamide prepn asthma pulmonary inflammation treatment; eosinophil apoptosis mediator benzamide acetanilide prepn
- IT Drug delivery systems
(aerosols; preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)
- IT Eosinophil
(apoptosis mediator; preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)
- IT Apoptosis
(eosinophil; preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)
- IT Antiasthmatics
Human
(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)
- IT Inflammation
(pulmonary inflammation treatment; preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)
- IT Asthma
(treatment; preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)
- IT 2210-77-7P 5294-61-1P 7728-40-7P 13327-12-3P 18865-38-8P
21236-54-4P 32795-44-1P 39942-49-9P 39942-50-2P 50295-20-0P
55340-20-0P 75549-83-6P 86523-70-8P 102240-67-5P 106134-54-7P
119053-70-2P 314769-17-0P 331758-55-5P 347196-34-3P 380204-72-8P
484027-66-9P 745789-55-3P 757134-36-4P 848176-38-5P 848441-42-9P
848441-43-0P 848441-44-1P 848441-45-2P **848441-46-3P**
848441-47-4P 848441-48-5P **848441-49-6P** 848441-50-9P
848441-51-0P 848441-52-1P 848441-53-2P
848441-54-3P 848441-55-4P 848441-56-5P 848441-57-6P
848441-58-7P 848441-59-8P 848441-60-1P
848441-61-2P 848441-62-3P 848441-63-4P
848441-64-5P **848441-65-6P** 848441-66-7P 848441-67-8P
848441-68-9P 848441-69-0P 848441-70-3P 848441-71-4P 848441-72-5P

848441-73-6P 848441-74-7P 848441-75-8P 848441-76-9P
848441-77-0P 848441-78-1P 848441-79-2P 848441-80-5P
 848441-81-6P 848441-82-7P 848441-83-8P 848441-84-9P 848441-85-0P
 848441-86-1P 848441-87-2P 848441-88-3P 848441-89-4P 848441-90-7P
 848441-91-8P 848441-92-9P 848441-93-0P 848441-94-1P 848441-95-2P
 848441-97-4P 848441-98-5P 848442-00-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT 51-06-9, Procainamide 75-04-7, Ethylamine, reactions 75-36-5, Acetyl chloride 92-54-6, N-Phenylpiperazine 98-88-4, Benzoyl chloride 100-52-7, Benzaldehyde, reactions 101-83-7, Dicyclohexylamine 103-69-5, N-Ethylaniline 103-71-9, Phenyl isocyanate, reactions 108-94-1, Cyclohexanone, reactions 109-01-3, N-Methylpiperazine 110-85-0, Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 112-64-1, Myristoyl chloride 122-78-1, Phenylacetaldehyde 123-75-1, Pyrrolidine, reactions 124-40-3, Dimethylamine, reactions **137-58-6, Lidocaine** 142-61-0, Hexanoyl chloride 544-64-9, cis-9-Tetradecenoic acid 614-39-1, Procainamide hydrochloride 618-46-2, 3-Chlorobenzoyl chloride 624-78-2 625-45-6, Methoxyacetic acid 638-29-9, Valeryl chloride 659-28-9, 4-Trifluoromethoxybenzaldehyde 764-85-2, Nonanoyl chloride 768-94-5, Adamantanamine 841-77-0, 1-Benzhydrylpiperazine 1008-91-9, 1-(4-Pyridyl)piperazine 1131-01-7 2051-28-7, Decahydroquinoline 2251-65-2, 3-Trifluoromethylbenzoyl chloride 2759-28-6, N-Benzylpiperazine 3173-56-6, Benzyl isocyanate 3360-41-6, 4-Phenylbutanol 4318-37-0, N-Methylhomopiperazine 4897-50-1, 1,4'-Bipiperidine 6530-09-2, 3-Aminoquinuclidine dihydrochloride 6874-67-5, Farnesyl bromide 10486-19-8, Tridecanal 13754-38-6, 1-Benzoylpiperazine 13889-98-0, 1-Acetylpiperazine 14002-51-8, 4-Phenylbenzoyl chloride 14649-03-7, (S)- α -Methylbenzyl isocyanate 16024-56-9 16024-58-1 18328-11-5, 4-Phenylbutyraldehyde 21655-48-1, cis-2,6-Dimethylpiperazine 25054-53-9, 3,4-Methylenedioxybenzoyl chloride 27578-60-5, N-(2-Aminoethyl)piperidine 32231-06-4 33375-06-3 34803-66-2 35037-73-1, 4-Trifluoromethoxyphenyl isocyanate 36823-88-8, 4-Trifluoromethoxybenzoyl chloride 50541-93-0, 4-Amino-1-benzylpiperidine 50606-96-7, 4-Heptylbenzoyl chloride 55579-01-6 67319-28-2, 2,5,8,11-Tetraoxatetradecanoic acid 67980-77-2, 1-(3-Pyridyl)piperazine 97664-54-5 112275-50-0, N-tert-Butoxycarbonylhomopiperazine 116258-17-4 287952-09-4 308103-51-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

IT 38870-89-2P, Methoxyacetyl chloride 848442-01-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)


IT **848441-46-3P 848441-49-6P 848441-51-0P**
848441-52-1P 848441-53-2P 848441-54-3P
848441-58-7P 848441-59-8P 848441-60-1P
848441-61-2P 848441-62-3P 848441-63-4P
848441-65-6P 848441-77-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)


RN 848441-46-3 HCAPLUS

CN Tetradecanamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-(9CI) (CA INDEX NAME)



RN 848441-49-6 HCAPLUS

CN 2,5,8,11-Tetraoxatetradecan-14-amide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-(9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— CH₂-NEt₂


RN 848441-51-0 HCAPLUS

CN Acetamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-methoxy-(9CI) (CA INDEX NAME)




RN 848441-52-1 HCAPLUS

CN Acetamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-[2-(2-methoxyethoxy)ethoxy]- (9CI) (CA INDEX NAME)




RN 848441-53-2 HCAPLUS

CN Acetamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-2-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 848441-54-3 HCAPLUS

CN Hexanamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]- (9CI) (CA INDEX NAME)




RN 848441-58-7 HCAPLUS

CN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-
[[[(phenylmethyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

RN 848441-59-8 HCAPLUS


CN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 848441-60-1 HCAPLUS

CN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[(1S)-1-phenylethyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 848441-61-2 HCAPLUS


CN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[(1R)-1-phenylethyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 848441-62-3 HCAPLUS

CN Acetamide, 2-(diethylamino)-N-[2,6-dimethyl-3-[[[R]-1-phenylethyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 848441-63-4 HCAPLUS


CN Benzamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-3-(trifluoromethyl)]- (9CI) (CA INDEX NAME)



RN 848441-65-6 HCAPLUS


CN 9-Tetradecenamide, N-[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-, (9Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 848441-77-0 HCAPLUS

CN 1H-1,4-Diazepine-1-acetamide, N-[2,6-dimethyl-3-[(1-oxotetradecyl)amino]phenyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




IT 137-58-6, Lidocaine

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of acetanilides and benzamides for the treatment of asthma and pulmonary inflammation)

RN 137-58-6 HCAPLUS

CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



L45 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1989:590987 HCAPLUS

DN 111:190987

ED Entered STN: 25 Nov 1989

TI Agglutination assay

IN Gibbons, Ian

PA Biotrack, Inc., USA

SO U.S., 12 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM G01N033-546

ICS G01N033-555; G01N033-563

INCL 436512000

CC 9-2 (Biochemical Methods)

Section cross-reference(s): 1

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | US 4829011 | A | 19890509 | US 1987-90027 | 19870827 |
| PRAI | US 1987-90027 | | 19870827 | | |

CLASS


| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|-------|---|
| US 4829011 | ICM | G01N033-546 |
| | ICS | G01N033-555; G01N033-563 |
| | INCL | 436512000 |
| US 4829011 | NCL | 436/512.000; 436/520.000; 436/533.000; 436/534.000; 436/805.000 |

AB A method of detecting the presence or amount of an analyte in a sample comprises forming a reaction medium containing (1) a sample; (2) particles having a binding pair member bound to their surfaces; and (3) a monovalent complementary partner to the binding pair member to which is attached an analyte mimic or analyte binding partner; and detecting the presence of agglutination of the particles in the reaction medium. In some embodiments a polyvalent receptor capable of binding both with the analyte and analyte mimic or with a 2nd binding site on the analyte is also introduced into the reaction medium. The invention is particularly useful for detecting the presence of analytes in whole blood, since red blood cells can act as the particles with the normal surface antigen of the red blood cells being used in the assay as the binding pair member. **Lidocaine** was determined in anticoagulated blood by agglutination assay using **lidocaine** conjugated to the Fab fragment of rabbit anti-human red blood cell antiserum (preparation given) and goat IgG to **lidocaine**. Agglutination was detected in a blank Prottime capillary flow cartridge by passing light from a germanium arsenide semiconductor laser through the cartridge. Decreasing **lidocaine** concentration resulted in an increase in agglutination.


ST agglutination assay; **lidocaine** agglutination assay blood
 IT **Latex**
 (binding pair member bound to, agglutination reagent containing)
 IT Particles
 (binding pair member bound to, agglutination test reagent containing)
 IT Blood analysis
 (by agglutination assay, reagents for)
 IT Receptors
 RL: ANST (Analytical study)
 (for analyte and analyte mimic, agglutination reagent containing)
 IT Agglutination
 (in anal., reagents for)
 IT Erythrocyte
 (surface antigen of, analyte or analyte mimic conjugate with antibody
 fragment to, for agglutination assay)
 IT Antibodies
 RL: ANST (Analytical study)
 (to erythrocyte surface antigen, conjugates with analyte or analyte
 mimic, agglutination reagent containing)
 IT Immunochemical analysis
 (agglutination test, reagents for)
 IT Antigens
 RL: ANST (Analytical study)
 (surface, of erythrocyte, antibody fragment to, analyte or analyte
 mimic conjugate with, for agglutination assay)
 IT **137-58-6, Lidocaine**
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, in blood, by agglutination assay)
 IT **67083-26-5**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in preparation of **lidocaine** conjugate with Fab
 fragment of rabbit anti-human erythrocyte antiserum)
 IT **137-58-6, Lidocaine**
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, in blood, by agglutination assay)
 RN 137-58-6 HCAPLUS
 CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT **67083-26-5**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in preparation of **lidocaine** conjugate with Fab
 fragment of rabbit anti-human erythrocyte antiserum)
 RN 67083-26-5 HCAPLUS
 CN Butanoic acid, 4-[[4-[[[(diethylamino)acetyl]amino]-3,5-
 dimethylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



L45 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1986:161422 HCAPLUS
 DN 104:161422
 ED Entered STN: 17 May 1986
 TI Homogeneous ferrocene-mediated amperometric immunoassay
 AU Di Gleria, Katalin; Green, Monika J.; Hill, H. Allen O.; McNeil, Calum J.
 CS Inorg. Chem. Lab., Univ. Oxford, Oxford, OX1 3QR, UK
 SO Analytical Chemistry (1986), 58(6), 1203-5
 CODEN: ANCHAM; ISSN: 0003-2700
 DT Journal
 LA English
 CC 1-1 (Pharmacology)
 Section cross-reference(s): 9, 15
 AB An amperometric immunoelectrode based on the ferrocene-mediated oxidation of glucose by glucose oxidase is described. An antigen-ferricinium ion complex was shown to act as an electron acceptor for glucose oxidase. The catalytic current produced in the enzymic oxidation of glucose was specifically inhibited upon binding the antigen-ferrocene complex with antibody. The inhibition could be reversed upon addition of free antigen. Thus, a homogeneous, competitive immunoassay was devised. **Lidocaine** [137-58-6] was chosen as the antigen. The assay time was 15 min, with a relative standard deviation of 3-6%.
 ST ferrocene amperometric immunoassay **lidocaine** blood
 IT Pharmaceutical analysis
 (ferrocene-mediated homogeneous amperometric immunoassay for)
 IT Immunochemical analysis
 (amperometric immunoassay, ferrocene-mediated homogeneous, in pharmaceutical anal.)
 IT 100205-71-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (amidation of, with **aminolidocaine**)
 IT 27951-88-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (amidation of, with methylferrocene carboxylic acid chloride)
 IT 137-58-6
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, in blood plasma by homogeneous amperometric immunoassay)
 IT 102-54-5D, drug conjugates
 RL: BIOL (Biological study)
 (for drug detns. by homogeneous amperometric immunoassays)
 IT 100205-70-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and use in **lidocaine** determination in blood plasma by homogeneous amperometric immunoassay)
 IT 137-58-6
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, in blood plasma by homogeneous amperometric immunoassay)
 RN 137-58-6 HCAPLUS
 CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




IT 100205-70-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use in lidocaine determination in blood plasma by
homogeneous amperometric immunoassay)


RN 100205-70-7 HCAPLUS

CN Ferrocene, 1-[[[4-[[[(diethylamino)acetyl]amino]-3,5-
dimethylphenyl]amino]carbonyl]-1',3-dimethyl- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



L45 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1985:481178 HCAPLUS
 DN 103:81178
 ED Entered STN: 22 Sep 1985
 TI Application of spin labeling to drug assays. IV. Spin- and radiolabeled lidocaine
 AU Yost, Yul; Holtzman, Jordan L.
 CS Res. Med. Serv., Veterans Adm. Med. Cent., Minneapolis, MN, 55417, USA
 SO Organic Preparations and Procedures International (1985), 17(4-5), 239-49
 CODEN: OPPIAK; ISSN: 0030-4948
 DT Journal
 LA English
 CC 1-1 (Pharmacology)
 Section cross-reference(s): 25, 27
 GI



AB Several spin-labeled derivs. of lidocaine (I) where the labels were linked to the glycine such as 2,2,6,6-tetramethyl-4-oxopiperidin-1-oxyl I derivative (II) [97729-44-7] or the xylidine moiety of I via a CO or NH2 group were prepared for use in determining free (non protein-bound) levels of I [137-58-6] in blood. To conduct competitive binding studies of spin-labeled I with proteins, radiolabeled I was also prepared
 ST lidocaine spin label prepn; serum protein binding
 lidocaine spin label
 IT Blood analysis
 (lidocaine determination in, spin labeling in evaluation of free and

protein-bound drug in relation to)

IT Proteins
RL: BIOL (Biological study)
(of blood serum, **lidocaine** binding by, spin-labeling technique in determination of)

IT Spin labels
(of **lidocaine**, for **lidocaine** free and protein-bound fraction determination in blood)

IT 137-58-6
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in blood, free and protein-bound drug in relation to)

IT 75-03-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(ethylation by, of tetramethylpyrrolidinaminoxyl derivative)

IT 1131-01-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(nitration of)

IT 97729-34-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and chlorination of)

IT 97729-37-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ethylation of)

IT 18865-38-8P 97729-42-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and ethylation with carbon-14 labeled Et bromide)

IT 97729-35-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with aminotetramethylpiperidineoxyl)

IT 50666-75-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with spin labels)

IT 39942-50-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with tetramethylpyrrolinoxylcarboxylic anhydride)

IT 39942-49-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

IT 57631-94-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and substitution reaction of)

IT 4919-40-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-chloroacetylation of)

IT 603-71-4P 97729-41-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 137-58-6DP, spin-labeled derivs. 97729-36-7P 97729-38-9P 97729-39-0P 97729-40-3P 97729-43-6P 97729-44-7P 97741-61-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for **lidocaine** free and protein-bound fraction determination in blood)

IT 13810-30-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with (aminodimethylphenyl)diethylaminoacetamide)

IT 14691-88-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with (chloroacetamido)dimethylbenzoyl chloride)

IT 34272-83-8 42585-33-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with (dimethylphenyl)iodoacetamide)

IT 25713-24-0 27048-01-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with diethylamine)


IT 31084-42-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with ethylamino(dimethylphenyl)acetamide)

IT 3095-38-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reduction of)

IT 109-89-7, biological studies
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (substitution reaction of, with chloro(dimethylnitrophenyl)acetamide)


IT 137-58-6
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, in blood, free and protein-bound drug in relation to)

RN 137-58-6 HCAPLUS
 CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




IT 137-58-6DP, spin-labeled derivs. 97741-61-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for lidocaine free and protein-bound fraction determination in blood)

RN 137-58-6 HCAPLUS
 CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 97741-61-2 HCAPLUS
 CN 1H-Pyrrol-1-yloxy, 3-[[[3-[[[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]amino]carbonyl]-2,5-dihydro-2,2,5,5-tetramethyl- (9CI) (CA INDEX NAME)



L45 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1978:444227 HCAPLUS
 DN 89:44227
 ED Entered STN: 12 May 1984
 TI Lidocaine antigens and antibodies
 IN Singh, Prithipal
 PA Syva Co., USA
 SO U.S., 9 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC C07G007-00
 INCL 195063000
 CC 34-2 (Synthesis of Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 25, 15, 63

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 4069105 | A | 19780117 | US 1977-775658 | 19770303 |
| | DE 2805962 | A1 | 19780907 | DE 1978-2805962 | 19780213 |
| | DE 2805962 | C2 | 19871223 | | |
| | JP 53108904 | A2 | 19780922 | JP 1978-19593 | 19780222 |
| | JP 02036599 | B4 | 19900817 | | |
| | AU 7833768 | A1 | 19790906 | AU 1978-33768 | 19780302 |
| | AU 513665 | B2 | 19801211 | | |
| | JP 01020451 | A2 | 19890124 | JP 1987-290422 | 19871117 |
| | JP 02043144 | B4 | 19900927 | | |
| | JP 03002199 | A2 | 19910108 | JP 1990-88991 | 19900403 |
| PRAI | US 1977-775658 | A | 19770303 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|-------|--|
| US 4069105 | IC | C07G007-00 |
| | INCL | 195063000 |
| US 4069105 | NCL | 530/363.000; 435/007.900; 435/188.000; 435/190.000; 435/961.000; 435/964.000; 436/517.000; 436/536.000; 436/543.000; 436/547.000; 436/816.000; 525/420.000; 528/328.000; 530/389.800; 530/391.900; 530/403.000; |

530/405.000; 530/406.000; 530/409.000; 530/806.000

GI



- AB **Lidocaine**-antigen conjugates I [R , R_1 = C1-4 alkyl; R_2 = H, Me; R_1R_2 = 6-membered ring with C and N; R_3 = R_4 = Me, R_3 = H, R_4 = Me, R_3 = Me, R_4 = H; Z = linking group; Q = poly(amino acid) (mol. weight at least 5,000), antigen, enzyme; n = 1 to number of available NH_2 groups of Q] were prepared as agents for the preparation of antibodies which can be used in competitive protein binding assays. Thus, aniline II (R_5 = H, R_6 = NO_2) was N-acylated with $ClCH_2COCl$ to give 73% anilide which was aminated with Et_2NH_2 to give 80% II (R_5 = Et_2NCH_2CO , R_6 = NO_2) which was hydrogenated over Adams' catalyst to give II (R_5 = Et_2NCH_2CO , R_6 = NH_2). The latter was treated with succinic anhydride to give II (R_5 = Et_2NCH_2CO , R_6 = $NHCOCH_2CH_2CO_2H$) (III) which was conjugated to bovine serum albumin (BSA) by iso-Bu chloroformate to give III-BSA conjugate.
- ST **lidocaine** antigen conjugate prepn antibody; glycine anilide antigen conjugate
- IT Albumins, blood serum
RL: PRP (Properties)
(conjugation of, with **lidocaine** derivative)
- IT Antibodies
RL: FORM (Formation, nonpreparative)
(formation of, to **lidocaine**-antigens conjugates)
- IT Enzymes
(**lidocaine** conjugates)
- IT Albumins, blood serum
Antigens
(**lidocaine** conjugates, preparation of)
- IT Peptides, preparation
(poly-, **lidocaine** conjugates)
- IT Globulins
RL: PRP (Properties)
(γ -, conjugation of, with **lidocaine** derivative)
- IT Globulins
(γ -, **lidocaine** conjugates, preparation of)
- IT 98-59-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation by, of dimethylaniline)
- IT 87-62-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, by tosyl chloride)
- IT 67083-29-8
RL: PRP (Properties)
(conjugation of, with glucose phosphate dehydrogenase)
- IT 9001-40-5
RL: PRP (Properties)
(conjugation of, with **lidocaine** derivative)
- IT 67083-26-5P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(preparation and conjugation of, with proteins)

IT 67083-25-4P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and conjugation of, with γ -globulin)

IT 67083-24-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and hydrogenation of)

IT 67083-22-1P 67083-27-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and hydrolysis of)

IT 4703-15-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and nitration of)

IT 16947-63-0P 67083-28-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, with chloroacetyl chloride)

IT 57631-94-4P 67083-23-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, with diethylamine)

IT 27951-88-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, with nitrophenyl chloroformate)

IT 9001-40-5DP, lidocaine conjugate 39942-49-9P
67083-25-4DP, γ -globulin conjugate 67083-26-5DP,
protein conjugates
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 79-04-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with aniline derivative)


IT 109-89-7, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloroacetanilide derivative)

IT 7693-46-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with lidocaine derivative)

IT 67083-29-8
RL: PRP (Properties)
(conjugation of, with glucose phosphate dehydrogenase)

RN 67083-29-8 HCAPLUS

CN Butanoic acid, 4-[[4-[[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]amino]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 67083-26-5P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and conjugation of, with proteins)

RN 67083-26-5 HCAPLUS

CN Butanoic acid, 4-[[4-[[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




IT 67083-25-4P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and conjugation of, with γ-globulin)

RN 67083-25-4 HCAPLUS

CN Carbamic acid, [4-[[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)




IT 67083-25-4DP, γ-globulin conjugate 67083-26-5DP,
protein conjugates

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 67083-25-4 HCAPLUS

CN Carbamic acid, [4-[[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 67083-26-5 HCAPLUS

CN Butanoic acid, 4-[[4-[[[(diethylamino)acetyl]amino]-3,5-dimethylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



L45 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1959:125066 HCAPLUS

DN 53:125066

OREF 53:22506d-e

ED Entered STN: 22 Apr 2001

TI Relations between chemical constitution and pharmacological activity in various types of new local anesthetics. V. Aminoacylamides and anilides; substitution in the acylated amino group

AU Koelzer, Paul P.; Wehr, Klaus H.

CS Med. Akad., Dusseldorf, Germany

SO Arzneimittelforschung (1958), 8, 609-15

CODEN: ARZNAD; ISSN: 0004-4172

DT Journal

LA Unavailable

CC 11H (Biological Chemistry: Pharmacology)

AB cf. ibid. 544. In compds. of the general formula ArN(R)OCR'N<, substitution of R by alkyl groups causes loss of local anesthetic activity and increased toxicity. Replacement of phenyl by other aryl groups or alkyl chains also results in reduction of anesthetic activity. Substitution of the terminal amino group by piperazine derivs. results in active compds. of pantocaine-like character.

IT Amides

(anesthetic action of)

IT Anilides

(anesthetics)

IT Anesthetics

Anesthetics

(local, action of)

IT 4-Piperidinecarboxy-2',6'-xylidide, 1-methyl-

(as local anesthetic)


IT 137-58-6, 2',6'-Acetoxylidide, 2-diethylamino-

(anesthetic action of)


IT 3213-14-7, o-Acetotoluidide, 2-diethylamino- 108951-43-5,

1-Pyrrolidineaceto-o-toluidide, 6'-chloro-
(as anesthetic)

IT 2210-77-7, 1-Pyrrolidineaceto-2',6'-xylidide 3213-12-5,
o-Acetotoluidide, 6'-chloro-2-diethylamino- 3847-42-5,
1-Pyrrolidineacetamide, N-1,2-diphenylethyl- 16417-75-7, Acetamide,
2-diethylamino-N-(2-methyl-1-naphthyl)- 31058-85-2, 2',6'-Acetoxyldide,
2-diethylamino-N-methyl- 37390-27-5, 1-Pyrrolidineacetamide,
N-diphenylmethyl- 46726-88-9, 1-Pyrrolidineaceto-o-toluidide
59960-80-4, Acetamide, 2-diethylamino-N-diphenylmethyl- 65446-95-9,
Acetanilide, 4'-chloro-2-diethylamino- 70289-10-0, o-Acetotoluidide,
6'-chloro-2-dimethylamino- 74816-25-4, Acetanilide, 4'-chloro-2-
diethylamino-N-methyl- 100318-28-3, 1-Pyrrolidineacetamide,
N-(4-methyl-3-pyridyl)- 100861-57-2, o-Acetotoluidide,
2-diethylamino-N-methyl- 101452-62-4, 1-Pyrrolidineacetamide,
N-1,5-dimethylhexyl-N-methyl- 101589-88-2, 4-Picoline,
2-(2-diethylaminoacetamido)- 101592-98-7, 1-Pyrrolidineacetamide,
N-undecyl- 101777-75-7, 1-Pyrrolidineacetamide, 2,5-dimethyl-N-(4-methyl-
3-pyridyl)- 101784-86-5, Acetamide, 2-diethylamino-N,N-diphenyl-
102310-07-6, Benzoic acid, p-(N-butyl-2-propylaminoacetamido)-, butyl
ester 102945-78-8, Benzoic acid, p-(N-butyl-2-piperidinoacetamido)-,
butyl ester 105474-63-3, o-Acetotoluidide, 6'-chloro-2-dimethylamino-N-
methyl- 106841-23-0, 1-Pyrrolidineacetamide, N-1,5-dimethyl-4-hexenyl-
108849-33-8, o-Acetotoluidide, 6'-chloro-2-diethylamino-N-methyl-
109476-32-6, 1-Pyrrolidineaceto-o-toluidide, N-acetyl-6'-chloro-
109615-38-5, o-Acetotoluidide, N-benzyl-6'-chloro-2-diethylamino-
110060-58-7, 1-Pyrrolidineaceto-o-toluidide, 6'-chloro-N-methyl-
111474-07-8, 1-Pyrrolidineaceto-2',6'-xylidide, N-butyl- α -methyl-
113454-93-6, 1-Pyrrolidineacetamide, N,N'-(2,4,6-trimethyl-m-
phenylene)bis- 114203-10-0, 1-Pyrrolidineaceto-2',6'-xylidide,
 α -phenyl- 119113-48-3, 2',6'-Propionoxylidide,
N-butyl-2-butylamino- 130987-85-8, Acetamide, 2-diethylamino-N-(1-
methyloctyl)- 131217-14-6, 1-Pyrrolidineacetamide, N-1,5-dimethyl-4-
hexenyl-N-methyl- 131590-07-3, o-Acetotoluidide, 2-diethylamino-N-ethyl-
132674-83-0, 2',6'-Acetoxyldide, N-butyl-2-ethylamino- 132752-39-7,
1-Pyrrolidineaceto-o-toluidide, N-ethyl- 132887-74-2,
1-Pyrrolidineaceto-2',6'-xylidide, N-methyl-
(as local anesthetic)
IT 137-58-6, 2',6'-Acetoxyldide, 2-diethylamino-
(anesthetic action of)
RN 137-58-6 HCAPLUS
CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) . (CA INDEX NAME)



IT 113454-93-6, 1-Pyrrolidineacetamide, N,N'-(2,4,6-trimethyl-m-
phenylene)bis-
(as local anesthetic)
RN 113454-93-6 HCAPLUS
CN 1-Pyrrolidineacetamide, N,N'-(2,4,6-trimethyl-m-phenylene)bis- (6CI) (CA
INDEX NAME)



L45 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1959:91300 HCAPLUS

DN 53:91300

OREF 53:16472i,16473a

ED Entered STN: 22 Apr 2001

TI Electrophoretic behavior of some local anesthetics

AU Baruffini, A.

CS Univ. Pavia, Italy

SO Farmaco, Edizione Pratica (1958), 13, 466-71 ←

CODEN: FRPPAO; ISSN: 0430-0912

DT Journal

LA Unavailable

CC 17 (Pharmaceuticals, Cosmetics, and Perfumes)

AB The anesthetics tested were benzocaine, procaine, butocaine, tutocaine, orthocaine, xylocaine, stovaine, cocaine, ambrostasine, cornecaine, and nupercaine. Conditions were 7 v./cm. for 3 hrs. on Schleicher and Schull paper 2043 B. The electrolyte was H3PO3, H3BO3, AcOH, and NaOH buffer which permits pH values 2-12 at constant ionic strength. The concentration of the

anesthetics was 1%. Aromatic amines were sprayed with 1% NaNO2 or 1% α-naphthol and 17% NH3. For aliphatic amines, Dragendorff's reagent was used. All compds. migrated sufficiently for analytical purposes. The rate of migration depended on the moles of the anesthetic and on the pH.

IT 1,2-Propanediol, 3-dimethylamino-, p-propylaminobenzoate
Ambrostasine


Orthoform or Orthoform-new
(electrophoresis of)

IT 50-36-2, Cocaine 59-46-1, Procaine 85-79-0, Dibucaine 94-09-7,
Benzocaine 137-58-6, 2',6'-Acetoxyidide, 2-diethylamino-
149-16-6, Butacaine 644-26-8, Amylocaine 891-33-8, Tutocaine
3686-68-8, Benzoic acid, p-propylamino-, 3-dimethylamino-2-hydroxypropyl
ester 23724-96-1, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-
(electrophoresis of)


IT 137-58-6, 2',6'-Acetoxyidide, 2-diethylamino- 23724-96-1
, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-
(electrophoresis of)

RN 137-58-6 HCAPLUS

CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 23724-96-1 HCAPLUS
 CN Acetamide, N,N'-1,2-phenylenebis[2-[(2-methylpropyl)amino]- (9CI) (CA
 INDEX NAME)




L45 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1959:91299 HCAPLUS
 DN 53:91299
 OREF 53:16472g-i
 ED Entered STN: 22 Apr 2001
 TI Separation of some tropaalkaloids by countercurrent distribution
 AU Siesto, A. J.
 CS Univ. Rome
 → SO Farmaco, Edizione Pratica (1958), 13, 445-58
 CODEN: FRPPAO; ISSN: 0430-0912
 DT Journal
 LA Unavailable
 CC 17 (Pharmaceuticals, Cosmetics, and Perfumes)
 AB The distribution of hyoscyamine, hyoscyne, and atropine in countercurrent distribution was studied in artificial mixts. and in natural plant exts. Partition coeffs. in the system CHCl3-phosphate buffer 0.5M (vols. 1:1), partition curves, and the ratios of log 10 K to the pH of the 3 alkaloids has been determined Hyoscyne seps. from hyoscyamine and atropine, but atropine does not sep. from hyoscyamine. The latter, after prolonged contact with the buffer solution, tends to be transformed by racemization into atropine. This prevents a separation which, theoretically, would be possible. Distribution curves were prepared with mixts. of the alkaloids of Atropa belladonna, Hyozcyamus niger, and Scopolia carniolica. The presence of some minor alkaloids was observed.
 IT Hyoscyamus niger
 (alkaloid separation from)
 IT Belladonna and(or) Atropa
 Scopolia carniolica
 (alkaloids of, separation of)
 IT Alkaloids
 (of belladonna, Hyoscyamus and Scopolia, separation of)
 IT 1,2-Propanediol, 3-dimethylamino-, p-propylaminobenzoate
 Orthoform or Orthoform-new
 (electrophoresis of)
 IT 85-79-0, Dibucaine 137-58-6, 2',6'-Acetoxylicide,
 2-diethylamino- 149-16-6, Butacaine 644-26-8, Amylocaine 3686-68-8,
 Benzoic acid, p-propylamino-, 3-dimethylamino-2-hydroxypropyl ester
 23724-96-1, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-
 (electrophoresis of)
 IT 51-34-3, Scopolamine 51-55-8, Atropine 101-31-5, Hyoscyamine
 (separation of)
 IT 137-58-6, 2',6'-Acetoxylicide, 2-diethylamino- 23724-96-1
 , Acetamide, N,N'-o-phenylenebis[2-isobutylamino-
 (electrophoresis of)
 RN 137-58-6 HCAPLUS

CN Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 23724-96-1 HCAPLUS

CN Acetamide, N,N'-1,2-phenylenebis[2-[(2-methylpropyl)amino]- (9CI) (CA INDEX NAME)



L45 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1958:67835 HCAPLUS

DN 52:67835

OREF 52:12211b-e

ED Entered STN: 22 Apr 2001

TI A local anesthetic derived from o-phenylenediamine:
N,N'-bis(isobutylaminoacetyl) - o-phenylenediamine

AU Tricerri, S.; Guzzon, V.

CS Ist. sieroterap. Milan. S. Belfanti

SO Farmaco, Edizione Scientifica (1957), 12, 954-9

CODEN: FRPSAX; ISSN: 0430-0920

DT Journal

LA Unavailable

CC 11H (Biological Chemistry: Pharmacology)

AB One mole o-phenylenediamine in 3 vols. AcOH and 2.2 moles ClCH₂COCl gives in the presence of NaOAc at room temperature 87% N,N' - bis(chloroacetyl) - o - phenylenediamine, m. 192-4°. Treating it with 5 moles iso-BuNH₂ in C₆H₆, first at room temperature, then by refluxing 8 hrs., filtering, evaporating in vacuo, dissolving in 2 l. H₂O containing 2 moles HCl, adjusting the pH to 6.5, decolorizing, and filtering, gave by alkalization 100% N,N'-bis(isobutylaminoacetyl)-o-phenylenediamine, m. 88-9°; HCl salt m. 264° (MeOH). The acute subcutaneous toxicity of the HCl salt in the mouse was L.D.50 940 mg./kg., in the guinea pig 850 to 1100 mg./kg. Subcutaneous instillation of a 2% solution in rabbits and guinea pigs was seemingly well tolerated. There was no reaction in the rabbit eye. Giving 1 cc. trypan blue intravenously 20 min. after a subcutaneous injection of 0.3 cc. caused a slight blue coloration at the site of injection, indicating a mild irritation. The min. hemolytic concentration was 2%. Doses of 1 mg./kg. caused

in the anesthetized rabbit a drop in blood pressure and an insignificant effect on respiration. The drug inhibited the spontaneous movements of


the isolated rabbit intestine and had a slight antihistaminic effect. Infiltration anesthesia in guinea pigs and humans showed a duration of 90 min. average, which was identical with that of **lidocaine**. In conduction anesthesia, the effect lasted longer than that of **lidocaine**.

IT Blood pressure
 (-lowering substances, N,N'-bis(isobutylaminoacetyl)-o-phenylenediamine as)
 IT Anesthetics
 (N,N'-bis(isobutylaminoacetyl)-o-phenylenediamine as local)
 IT Intestines
 (N,N'-bis(isobutylaminoacetyl)-o-phenylenediamine effect on)
 IT 2810-42-6, Acetamide, N,N'-o-phenylenebis[2-chloro- 103267-80-7, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dipicrate 107924-26-5, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dihydrochloride
 (preparation of)
 IT 103267-80-7, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dipicrate 107924-26-5, Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dihydrochloride
 (preparation of)
 RN 103267-80-7 HCAPLUS
 CN Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dipicrate (6CI) (CA INDEX NAME)

CM 1

CRN 23724-96-1


CMF C18 H30 N4 O2



CM 2


CRN 88-89-1

CMF C6 H3 N3 O7



RN 107924-26-5 HCAPLUS

CN Acetamide, N,N'-o-phenylenebis[2-isobutylamino-, dihydrochloride (6CI)
 (CA INDEX NAME)



● 2 HCl

=> => d all hitstr

L47 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1976:35324 HCAPLUS
 DN 84:35324
 ED Entered STN: 12 May 1984
 TI Polymeric local anesthetic and antiarrhythmic agents
 IN Okamoto, Yoshiyuki; Riker, Walter F., Jr.; Udenfriend, Sidney
 PA Hoffmann-La Roche, Inc., USA
 SO U.S., 10 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC C07C
 INCL 260472000
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 25, 35
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 3914283 | A | 19751021 | US 1973-423644 | 19731210 |
| PRAI | US 1973-423644 | A | 19731210 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|-------|--|
| US 3914283 | IC | C07C |
| | INCL | 260472000 |
| US 3914283 | NCL | 560/049.000; 514/818.000; 514/821.000; 548/524.000; 548/540.000; 564/194.000 |

AB Polymers comprising repeating units of local anesthetics covalently bonded by an amide linkage to a group derived from a carboxyl of a polymeric acid backbone exhibit local anesthetic and antiarrhythmic activities similar to the parent moiety but with longer duration. Thus, poly(acrylylprocaine) [57635-62-8] was prepared by polymerization of acrylylprocaine [25252-96-4] or reaction of poly(acryloyl chloride) [25189-84-8] with procaine-HCl [51-05-8]. The polymeric local anesthetics exhibited a slower onset and development of toxic effects and a longer duration of these effects than their comparable anesthetics. All of the polymers and their monomers produced a reversible conduction block of the compound action potential in frog sciatic nerve in vitro. Thus, these compds. were indistinguishable from the prototype local anesthetics. Also the polymers administered i.v. to the cat, variably suppressed the development of epinephrine-induced ectopic ventricular beats, again similar to the parent moieties.

ST polymer local anesthetic; antiarrhythmic polymer local anesthetic
 IT Heart, disease or disorder

(arrhythmia, local anesthetic polymers for treatment of)

IT Anesthetics
(local, polymers)

IT Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester, monohydrochloride,
reaction product with polyacryloyl chloride
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiarrhythmic and local anesthetic with prolonged
action)

IT 1131-01-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and nitration of)

IT 39942-50-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction with acryloyl chloride)

IT 57631-94-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction with diethylamine)

IT 39942-49-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reduction of)

IT 25189-84-8P 25252-96-4P 57631-91-1P 57631-92-2P
57631-93-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 25189-84-8DP, 2-Propenoyl chloride, homopolymer, reaction products with
procaine 57635-62-8P 57635-63-9P 57635-64-0P 57635-65-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiarrhythmic and local anesthetic with prolonged
action)

IT 614-39-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with acryloyl chloride)

IT 87-62-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloroacetyl chloride)

IT 109-89-7, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with chloroacetyl amino(dimethyl)nitrobenzene)


IT 79-04-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with dimethylaniline)

IT 814-68-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with local anesthetics)

IT 57631-91-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 57631-91-1 HCAPLUS

CN 2-Propenamide, N-[3-[(diethylamino)acetyl]amino]-2,4-dimethylphenyl]-
(9CI) (CA INDEX NAME)



IT 57635-63-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as antiarrhythmic and local anesthetic with prolonged action)


RN 57635-63-9 HCAPLUS

CN 2-Propenamamide, N-[3-[[diethylamino]acetyl]amino]-2,4-dimethylphenyl]-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 57631-91-1

CMF C17 H25 N3 O2



=> d his

(FILE 'HCAPLUS' ENTERED AT 09:28:10 ON 05 AUG 2005)

DEL HIS

E CHU V/AU

L1 173 S E3,E6,E26,E32,E33

E TENG Z/AU

L2 22 S E3-E5 OR TENG ZHU?/AU

E LEWISCH S/AU

L3 5 S E4

E EDWARDS R/AU

L4 306 S E3,E20-E22

E EDWARDS RON/AU

L5 4 S E3,E6,E13

L6 510 S L1-L5

L7 0 S L6 AND ?LIDOCAIN?

L8 8 S L6 AND BENZ?/SC,SX

L9 0 S L1 AND L2-L5

L10 0 S L2 AND L3-L5

L11 0 S L3 AND L4,L5

L12 0 S L4 AND L5

jan delaval - 5 august 2005

FILE 'REGISTRY' ENTERED AT 09:30:46 ON 05 AUG 2005

L13 STR
L14 50 S L13
L15 5958 S L13 FUL
SAV L15 KUMAR828/A
L16 0 S L15 AND C21H37N5O2
L17 0 S L15 AND C24H41N5O5
L18 STR L13
L19 2 S L18 SAM SUB=L15
L20 18 S L18 FUL SUB=L15
SAV L20 KUMAR828A/A
L21 332 S L15 AND PMS/CI
L22 0 S L21 AND (LATEX OR STARCH)
L23 1 S STARCH/CN
L24 0 S 9005-25-8/CRN AND L15
L25 16 S L15 AND OC2/ES

FILE 'HCAPLUS' ENTERED AT 09:47:08 ON 05 AUG 2005

L26 2747 S L15
L27 0 S L6 AND L26
L28 0 S L26 AND (DADE? OR BEHRING? OR DEUTSCHE BANK?)/PA,CS
L29 6 S L26 AND ?LIDOCAIN?

FILE 'REGISTRY' ENTERED AT 09:49:05 ON 05 AUG 2005

L30 1 S LIDOCAINE/CN
L31 248 S 137-58-6/CRN

FILE 'HCAPLUS' ENTERED AT 09:49:28 ON 05 AUG 2005

L32 7 S L30 AND L26
L33 0 S L31 AND L26
L34 9 S L29,L32
L35 42 S L26 AND ?LATEX?
L36 37 S L26 AND ?RUBBER?
L37 7 S L26 AND ?ELASTOM?
E LATEX/CT
E E3+ALL
L38 6573 S E4+NT
E E10+ALL
L39 14600 S E6+OLD,NT
L40 4 S L26 AND L38,L39

FILE 'REGISTRY' ENTERED AT 09:53:32 ON 05 AUG 2005

L41 STR L18
L42 50 S L41 SAM SUB=L15
L43 2298 S L41 FUL SUB=L15

FILE 'HCAPLUS' ENTERED AT 09:55:22 ON 05 AUG 2005

L44 1 S L34 AND L35-L37,L40
L45 9 S L34,L44

FILE 'REGISTRY' ENTERED AT 09:56:16 ON 05 AUG 2005

FILE 'HCAPLUS' ENTERED AT 09:56:53 ON 05 AUG 2005

L46 3 S L20
L47 1 S L46 NOT L45

=>